HIV PEP
BASHH regimen: emtricitabine/tenofovir (Truvada) AND raltegravir
| Given following possible exposure to HIV | |
|---|---|
| Indication: | Typically after UPSI with HIV+, viral load +ve person (risk with anal > vaginal) |
| Mechanism of action: | Inhibit early viral replication (emtricitabine with tenofovir disoproxil plus raltegravir) |
| Advantages: | Usually well tolerated Reduces likelihood of seroconversion by 80% |
| Adverse effects: | - |
| Contraindications: | Severe renal/liver failure. Stopping Truvada may rarely trigger flare of Hep B Should not be taken with Rifampicin |
| Administration: | 28d course, starting no later than 72h from exposure. Starter packs in A&E typically only cover 3-5 days - refer to sexual health clinic |
other important considerations
- is there a risk of co-infection?
- some sources quote 82% of HIV infected individuals to be co-infected with Hepatitis C, however there is no PEP available